Tagged with Infectious Disease

France As global vaccine development grows more complex and capital more selective, Valneva is sharpening its identity and returning decisively to its roots. The company’s decision to close its Nantes site and re-centralise French operations in Lyon is more than operational streamlining; it signals a strategic recommitment to one of Europe’s…

Switzerland Jürg Utzinger, Director of the Swiss Tropical and Public Health Institute (Swiss TPH), addresses global health challenges, the significance of partnerships and the impact of new technologies on health outcomes. He states, “Our mission is to make the world a healthier place, focusing on topics such as climate change, infectious…

Africa While HIV has shifted from a death sentence to a manageable disease in most developed nations, there are several reasons why it still represents a huge global issue. It remains highly infectious and difficult to detect in the early stages of infection, while existing treatments are unavailable or too expensive…

Italy Nicoletta Luppi, MSD Italia’s Senior Vice President & Managing Director details the need for healthcare reform in Italy and walks us through MSD’s portfolio priorities. In addition, she explains the Italian affiliate’s Equity and Inclusion initiatives.  Since the Organon spinoff, the strategy to focus on specific parts of the portfolio…

Asia-Pacific We spoke to Dr Sarthak Das, Chief Executive Officer of the Asia Pacific Leaders Malaria Alliance (APLMA), about the region’s progress towards malaria eradication and the organisation’s priorities, now that its target date for a malaria-free Asia Pacific is just eight years away. … if you compare [malaria] to other…

Puerto Rico Based in Tampa, Florida, Romark is a research-based pharmaceutical company focused on developing innovative treatments for infectious diseases. The company recently inaugurated its first finished products manufacturing facilities in Puerto Rico, transforming itself into a vertically integrated organization. CEO Marc Ayers extols the strengths of Puerto Rico as manufacturing location…

Sweden Infectious diseases kill over 17 million people each year, according to the WHO, which is why vaccine-specialist Valneva is continuing to grow and develop the next generation of vaccines. Janet Hoogstraate, chair of the Management Board of Valneva Sweden, explains the high-quality of their manufacturing operations in the country and…

Taiwan United Biomedical, Inc. (UBI) is dedicated to the discovery, development, and commercialization of immunotherapies & vaccines for chronic and infectious diseases and is passionate about delivering science-driven innovation with platform capabilities. Chang Yi Wang is the Chairperson and CSO of United BioPharma (UBP), a member of the UBI group of…

Thailand Thailand has experienced a steady decline in infectious disease rates in the last generation thanks to the country’s commitment to life sciences research. The executive vice president of the National Science and Technology Development Agency elaborates on Thailand’s research on infectious diseases and how collaboration fuels further progress.    We…

Thailand Dr Kumthorn Malathum, president of the Infectious Disease Association of Thailand, shares his insight on the issue of infectious disease in the country and the need to develop collaboration in order to tackle these infections.   Due to the country’s climate and people’s way of life, infectious diseases are a…

Algeria Nadia Oka-Bousbia of bioMérieux Algeria discusses the affiliate’s important role within Algeria’s fight against infectious diseases and the training of health managers, difficulties surrounding import restrictions, and the company’s constantly-evolving strategy for the future.   These are exciting times for bioMérieux locally. We understand that earlier this year, your global…

Ecuador Angel Guevara, molecular biologist and professor at the Central University of Ecuador (UCE), discusses Ecuador’s potential as a clinical trial destination, a diverse tropical country with high prevalence of infectious disease and educated healthcare professionals. He explains the differences between public and private healthcare services, notably from the point of…